Postpartum depression affects roughly 1 in 7 new mothers, causing persistent sadness, anxiety, difficulty bonding with the baby, and — in severe cases — thoughts of self-harm. It remains dramatically underrecognized and undertreated, and effective treatment exists.
What's actually going on in research
Zuranolone, an oral neurosteroid that rapidly modulates GABA-A receptors, is now approved for postpartum depression with a 14-day course that works far faster than traditional antidepressants. Brexanolone (an IV neurosteroid) is the first drug specifically designed for PPD. Trials are testing telehealth delivery of psychotherapy, peer support models, and digital interventions to reach the many mothers who never access formal care.
Neurosteroid treatment
Zuranolone (oral) and brexanolone (IV) act on GABA-A receptors to rapidly reduce postpartum depression symptoms in days rather than weeks, representing a new mechanism class.
Digital and telehealth therapy
App-based CBT and telehealth-delivered interpersonal therapy are being tested for postpartum depression, potentially reaching mothers who face barriers to in-person mental health care.
Peer support programs
Structured programs pairing mothers with trained peer supporters who have recovered from PPD are in trials for their ability to reduce symptoms and improve treatment engagement.
What to know before you search
Eligibility requires a postpartum depression diagnosis within a defined number of weeks after delivery, depression severity threshold, and exclusion of psychosis or bipolar features.
What types of trials are currently open
- Drug trials — Testing neurosteroids, antidepressants, and novel agents for postpartum depression symptom relief.
- Psychotherapy trials — Comparing CBT, interpersonal therapy, and other structured psychotherapies delivered in-person and digitally.
- Prevention trials — Testing progesterone supplements, psychoeducation, and support interventions in high-risk pregnant women.
- Digital intervention trials — Evaluating app-based and telehealth programs to extend access to postpartum depression treatment.
- Observational studies — Tracking PPD screening rates, treatment access, and child developmental outcomes.
Recently added Postpartum Depression trials
Sexual Health Education During Pregnancy
This experimental, randomized controlled, single-blind study includes intervention and control groups. Pregnant women between 16 and 20 weeks of gestation who meet the inclusion criteria and agree to participate will be included in the study. Pregnant women will be randomly assigned to groups. Pre-test data will be collected from both groups. The intervention group will receive sexual counseling training in two sessions, face-to-face and in groups, until week 22. Second test data will be collected after week 37 (before delivery), and final test data will be collected three months after delivery. This study is expected to have a significant impact on women's lives, as this topic is considered taboo in our country, leading to a lack of open discussion and the prevalence of misconceptions and false beliefs (sexual myths).
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy, singleton infant 2-60 months before enrollment in the study and are aged 22 years and older, but under the age of 60 years. The main question it aims to answer is: Does the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices improve depressive symptoms and urinary incontinence? Participants will be asked to: Undergo twelve treatments Complete the Patient Health Questionnaire-9 Complete the 6-item Hamilton Depression Rating Scale Complete the Edinburgh Postnatal Depression Scale Complete the Therapy Comfort Questionnaire Complete the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form Complete the Female Sexual Function Index Complete the Warwick-Edinburgh Mental Wellbeing Scale Complete the Columbia Suicide Severity Rating Scale-Screen Version Complete the Subject Satisfaction Questionnaire Complete the Therapy Comfort Questionnaire
Find Postpartum Depression trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.